The specific aim of this proposal is to provide advanced training to clinician scientists to pursue an academic career in translational research related to cardiovascular gene therapy. Most physicians at the completion of their medical or surgical training do not possess the knowledge or skills needed to implement a basic clinical trial, let alone one utilization gene therapy vectors. Thus, a training program to accomplish these goals must provide exposure to the conduct of a clinical trial, data analysis, medical ethics, and regulatory affairs pertaining to human gene therapy, as well as basic molecular biology skills. We have designed a two-year cardiovascular gene therapy training for two Clinician Scientist trainees per year. We have assembled a diverse group of faculty members that include clinical investigators, molecular biologists, gene therapists, immunologists, pharmacologists, bioengineers, epidemiologists, statisticians, and bioethicists. During the first year, the Clinician Scientist trainees will participate in the NHLBI-funded Clinical Research Training Program (CRTP) established at the University of Pittsburgh. The CRTP aims to teach the skills necessary to design and conduct high quality clinical research. We will utilize the core curriculum and integrated seminar series of the CRTP as part of the training plan to avid unnecessary duplication of resources and allow of immediate implementation. Also, during the first year, each trainee will be assigned to one of the ongoing clinical Cardiovascular Gene Therapy projects to get early exposure to a human gene therapy trial. During the second year, the trainees will participate in the management of active clinical trials through the PCRN and the GCRC. The Pittsburgh Clinical Research Network (PCRN) is a clinical research organization that provides site management services for the conduct of industry-sponsored research. The General Clinical Research Center (GCRC) provides the infrastructure and support staff required for the conduct of clinical research and gene therapy trials at the University of Pittsburgh. The second year of training will also include three Gene Therapy Research Modules with basic coursework and laboratory experience focusing on gene therapy issues. The overall educational goals are to train physicians to conduct clinical gene therapy research related to cardiovascular disease and become competitive in seeking research support for clinical trials. It is expected that each trainee will submit an independent clinical trial proposal within a year of completing the training program.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01HL066949-01S1
Application #
6434104
Study Section
Special Emphasis Panel (ZHL1)
Project Start
2001-03-15
Project End
2001-08-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
$292,370
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Laemmle, Lillian L; Cohen, Justus B; Glorioso, Joseph C (2016) Constitutive Expression of GATA4 Dramatically Increases the Cardiogenic Potential of D3 Mouse Embryonic Stem Cells. Open Biotechnol J 10:248-257
Goins, William F; Hall, Bonnie; Cohen, Justus B et al. (2016) Retargeting of herpes simplex virus (HSV) vectors. Curr Opin Virol 21:93-101
Zhu, Xiaodong; McTiernan, Charles F; Rajagopalan, Navin et al. (2012) Immunosuppression decreases inflammation and increases AAV6-hSERCA2a-mediated SERCA2a expression. Hum Gene Ther 23:722-32
Ramani, Ravi; Nilles, Kathleen; Gibson, Gregory et al. (2011) Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling. Clin Transl Sci 4:24-31
Yoshimura, Naoki; Kato, Ryuichi; Chancellor, Michael B et al. (2010) Gene therapy as future treatment of erectile dysfunction. Expert Opin Biol Ther 10:1305-14
Frampton Jr, Arthur R; Uchida, Hiroaki; von Einem, Jens et al. (2010) Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells. Vet Microbiol 141:12-21
Kato, R; Wolfe, D; Coyle, C H et al. (2009) Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury. Gene Ther 16:26-33
Peng, Fuwang; Dhillon, Navneet K; Yao, Honghong et al. (2008) Mechanisms of platelet-derived growth factor-mediated neuroprotection--implications in HIV dementia. Eur J Neurosci 28:1255-64
Cardinal, Jon; Klune, John Robert; Chory, Eamon et al. (2008) Noninvasive radiofrequency ablation of cancer targeted by gold nanoparticles. Surgery 144:125-32
Li, Han; Baskaran, Rajasekaran; Krisky, David M et al. (2008) Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement of virus growth. Virology 375:13-23

Showing the most recent 10 out of 40 publications